HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc..
We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
AIDS (London, England) - 38(2024), 4 vom: 15. März, Seite 607-610 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
VanderVeen, Laurie A [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 29.02.2024 Date Revised 03.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1097/QAD.0000000000003792 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369064747 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369064747 | ||
003 | DE-627 | ||
005 | 20240303232000.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240229s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/QAD.0000000000003792 |2 doi | |
028 | 5 | 2 | |a pubmed24n1315.xml |
035 | |a (DE-627)NLM369064747 | ||
035 | |a (NLM)38416554 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a VanderVeen, Laurie A |e verfasserin |4 aut | |
245 | 1 | 0 | |a HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.02.2024 | ||
500 | |a Date Revised 03.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
520 | |a We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
700 | 1 | |a Selzer, Lisa |e verfasserin |4 aut | |
700 | 1 | |a Moldt, Brian |e verfasserin |4 aut | |
700 | 1 | |a Parvangada, Aiyappa |e verfasserin |4 aut | |
700 | 1 | |a Li, Jiani |e verfasserin |4 aut | |
700 | 1 | |a Ananworanich, Jintanat |e verfasserin |4 aut | |
700 | 1 | |a Crowell, Trevor A |e verfasserin |4 aut | |
700 | 1 | |a Eron, Joseph J |e verfasserin |4 aut | |
700 | 1 | |a Daar, Eric S |e verfasserin |4 aut | |
700 | 1 | |a Haubrich, Richard |e verfasserin |4 aut | |
700 | 1 | |a Geleziunas, Romas |e verfasserin |4 aut | |
700 | 1 | |a Cyktor, Joshua |e verfasserin |4 aut | |
700 | 1 | |a Mellors, John W |e verfasserin |4 aut | |
700 | 1 | |a Callebaut, Christian |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 38(2024), 4 vom: 15. März, Seite 607-610 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2024 |g number:4 |g day:15 |g month:03 |g pages:607-610 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000003792 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 38 |j 2024 |e 4 |b 15 |c 03 |h 607-610 |